ADRX Andrx

Andrx Corporation (NASDAQ:ADRX) today announced that it plans to issue its 2006 second quarter financial results press release and file its Form 10-Q on Tuesday, August 8, 2006, after the market close. Due to the pending acquisition by Watson Pharmaceuticals, Inc., Andrx has decided not to conduct a conference call this quarter. About Andrx Corporation We are a pharmaceutical company that: -- develops and commercializes generic versions of primarily controlled-release pharmaceutical products as well as oral contraceptives, and selective immediate-release products; -- distributes pharmaceutical products, primarily generics, which have been commercialized by others, as well as our own, primarily to independent and chain pharmacies and physicians' offices; and -- develops and manufactures pharmaceutical products for other pharmaceutical companies, including combination products and controlled-release formulations. Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should", "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including but not limited to: which sanctions, if any, the FDA may seek in connection with its decision to place the Company in Official Action Indicated (OAI) status or after any current or future inspections, including without limitation sanctions relating to any failure to comply with current Good Manufacturing Practices (cGMP) requirements and if and when the "hold" on pharmaceutical product applications will be lifted; whether the Company will be able to satisfactorily resolve the FDA's April 2006 483 - List of Inspectional Observations; the Company's dependence on a relatively small number of products; licensing revenues; the timing and outcome of litigation and future product launches; government regulation; competition; manufacturing capacities; safety issues; output and quality processes; the potential loss of senior management and other key personnel; and the completion of our merger with Watson Pharmaceuticals, Inc. Andrx Corporation is also subject to other risks detailed from time to time in its filings with the U.S. Securities and Exchange Commission. Andrx disclaims any responsibility to update the statements contained herein. This release and additional information about Andrx Corporation are also available on the Internet at: http://www.andrx.com.